Breast cancer is the most common malignant tumor of women in the world，which greatly threatens patients' health. Neoad－juvant therapy can not only increase the proportion of breast conserving surgery，but also can test internal sensitivity of treatments' efficacy. Especially in triple negative and Her-2 overexpression subtypes，pathological complete response is an important predictor of long-term prognosis. However，the overall prognosis of most patients with estrogen receptor（ER） positive breast cancer is good，but clinicians lack reliable evidence for decision-making between neoadjuvant endocrine therapy and neoadjuvant chemotherapy due to the lack of accurate and convenient predictors. In order to reduce side effects caused by unnecessary chemotherapy，it is urgent to find new predictive markers for neoadjuvant endocrine therapy. This paper reviewed applications and limitations of prognostic markers in current neoadjuvant endocrine therapy to treat ER+ breast cancer，and the current status of new biomarkers.